Clinical Trials Directory

We are doing this study to see if radiation and chemotherapy can be done instead of an extensive surgical removal of the groin lymph nodes for patients with vulvar cancer whose disease has spread to the sentinel node. We are doing this study because we want to find out if this approach is better or worse than the usual approach for vulvar cancer.

We are doing this study to find out if the study drugs nivolumab and ipilimumab are a safe and effective option for people who have endometrial cancer that does not respond to standard treatment and/or has spread to other parts of the body. We want to compare the results of using these 2 drugs together versus using nivolumab alone.

We are doing this study to improve how cancer patients and their providers communicate with each other. We want to know how personal biases can affect how cancer care is explained and managed. We think being able to identify bias if any exists can improve care and patients' psychological well-being.

We are doing this study to improve how patients and their primary care providers can keep up with routine health maintenance during cancer treatments. We want to know if a new model of communication between patients and their doctors can improve health outcomes.

We are doing this study to learn whether a radiation therapy boost in combination with chemotherapy and immunotherapy before surgery helps the immune system to destroy cancer cells.

We are doing this study to find out how well an experimental multi-cancer early detection (MCED) test works. We want to know if this test is accurate and if it provides a good benefit for study participants and medical providers.

We are doing this study to understand whether people who receive a lower radiation dose after an interim (the second scan) PET-CT identifies an early treatment response have a similar outcome to those receiving standard radiation dose.

The results of the interim PET-CT scan will be used guide your radiation dose plan. Depending on the PET-CT results, you will either received a reduced radiation dose or the standard radiation dose for your cancer.

We are doing this study to see if taking a prebiotic (dietary supplement) can reduce the risk of acute graft-versus-host disease (a common complication) in people who receive an allogeneic stem cell transplant. This study is important because prebiotics are a common and safe dietary supplement, and there is a need for a safe and effective way to reduce graft-versus-host disease after transplant.